Pfizer Inc. (PFE) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Pfizer Inc. (PFE) advanced +1.70% to $29.95 as options desks priced 59% call premium vs. 41% put protection around the $29 max-pain magnet. Solid 74% profit margin (5% return on capital), mixed timing at 22x P/E—hold if owned, no rush to chase.
Tech giants are pouring an estimated US$828b into AI infrastructure in 2026, and a chunk of that horsepower is already flowing into healthcare. When that much capital chases one idea, the risk is ignoring where it quietl
Pfizer's post-COVID comeback is still only in the early stages.
Preview next weekâs market movers: jobs data, PMI reports, major earnings from Apple and AMD, and IPO buzz. Read here for more details.
Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity, with Phase 3 injection results expected in 2027. Read why VKTX stock is a hold.
S&P 500 most-active stocks on Oct. 30, 2026 included Reddit and Marvell double-digit declines, while AT&T, Pfizer and Keurig Dr Pepper rose.
BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
Players: Pfizer, Novartis, Bayer, Astellas and Sarepta. Profile: next-gen AAV delivery, including engineered capsids, targeting, safety and scalable manufacturing.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Next-Generatio
AbbVie posts strong Q3 growth, Skyrizi sales surge, and 2026 EPS guidance rises. Click for this ABBV earnings update.
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or pile in, the real story behind that coverage gap deserves a
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PFE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PFE. Explore sector supply chains on /butterfly.
Why PFE Stock advanced +1.70% Today — RQD Quant Desk Flash. Solid 74% profit margin (5% return on capital), mixed timing at 22x P/E—hold if owned, no rush to chase.